17,261 trials
Dysmenorrhea
Primary: The Primary Outcome Was Total Pain Relief Over 4 Hours (TOPAR4), Comparing a Single Dose of Sildenafil 100 mg to a Single Dose of Placebo. — 11.9; 6.4 units on a scale…
Hyperlipidemia
Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12 — -14.76; -40.77; -42.58; -50.70 percent change — p=<0.001
Myasthenia Gravis
Primary: Total Prednisone Dose Area Under the Curve — 2996.6; 3484.7 mg*Months — p=0.26
Dry Eye · Sjogren's Syndrome · Graft vs. Host Disease
Primary: Safety — 0; 0 event
HIV-1 Infection
Primary: Medroxyprogesterone Acetate (MPA) Pharmacokinetic Parameter (PK) Area Under the Concentration-time Curve (AUC0-12weeks) — 18.08 ng*wk/mL
Lymphoma
Primary: Progression-free Survival Rate — 1.759 years
Symptomatic Atrial Fibrillation · Atrial Flutter
Primary: Conversion to Sinus Rhythm — 4; 4; 11; 13 participants
Heparin-induced Thrombocytopenia Type II
Primary: Composite of All-cause Death, Thrombosis (New and Extended) and Unplanned Amputation — 10 participants
Atherosclerosis · Vascular Disease · Arteriosclerosis
Primary: Angiographic Late Lumen Loss — 0.46; 1.09 mm — p=0.016
Renal Cell Carcinoma · Graft-Versus-Host Disease · Engraftment Syndrome
Primary: Clinical Regression of Metastatic Renal Cell Carcinoma (Partial Response (PR)) or Complete Remission of Tumor (Complete Response (CR)) — 0; 0; 8; 1 participants
In-Stent Restenosis
Primary: Percent Diameter Stenosis (%DS) in the Analysis Segment — 36.0 Percentage stenosis of vessel diameter
Hypertension
Primary: Mean Nighttime Systolic Blood Pressure (SBP) — 126.6; 125.3 mmHg — p=0.075
Hypertension
Primary: Mean Nighttime Systolic Blood Pressure (SBP) — 126.6; 127.9 mmHg — p=0.0269
Multiple Myeloma
Primary: Phase 1: Maximum Tolerated Dose (MTD) — 3.7 mg
Melanoma
Primary: Objective Tumor Response Rate — 28 percentage of participants